huGPAM Mouse
製品名
huGPAM Mouse
製品ID
C002018
系統名
C57BL/6NCya-Gpamtm1(hGPAM)/Cya
背景情報
C57BL/6NCya
状況
このマウス系統を論文で使用する場合は、「huGPAM Mouse（カタログ番号C002018）はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
遺伝子名
遺伝子別名
GPAT, GPAT1
NCBI ID
染色体
Chr 10
MGI ID
さらに
系統詳細
GPAM (Glycerol-3-phosphate acyltransferase, mitochondrial) is a mitochondrial outer membrane-associated acyltransferase and one of the key rate-limiting enzymes involved in triglyceride biosynthesis, primarily expressed in metabolic tissues including the liver and adipose tissue [1-2]. GPAM participates in triglyceride and phospholipid synthesis, lipid storage, and energy metabolism regulation, and is closely associated with mitochondrial homeostasis and lipid metabolic reprogramming [2-3]. Studies have shown that aberrant GPAM expression or dysfunction is associated with the pathogenesis of metabolic disorders, including Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Metabolic Dysfunction-Associated Steatohepatitis (MASH), obesity, and insulin resistance. Therefore, GPAM is considered a potential therapeutic target for metabolic diseases, and studies on GPAM inhibitors and related mechanisms have been conducted [3-4].
The huGPAM mouse is a humanized model generated by replacing the sequences from the start codon to downstream of the 3'UTR of the mouse Gpam gene with the sequences from the start codon to downstream of the 3'UTR of the human GPAM gene. This model can be used for in vivo pharmacodynamic and safety evaluation of GPAM-targeted candidate therapeutics and is also applicable for studies of the pathogenesis and progression of metabolic disorders, including Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Metabolic Dysfunction-Associated Steatohepatitis (MASH), obesity, and lipid metabolism disorders, as well as lipid metabolic regulatory networks and combination therapeutic strategies.
参考文献
Yet S F, Lee S, Hahm Y T, et al. Mitochondrial glycerol-3-phosphate acyltransferase expression in human tissues and its functional characterization[J]. Biochemical Journal, 1998, 331(Pt 3): 809-816.
Hammond L E, Gallagher P A, Wang S, et al. Mitochondrial glycerol-3-phosphate acyltransferase-deficient mice have reduced weight and liver triacylglycerol content and altered glycerolipid fatty acid composition[J]. Molecular and Cellular Biology, 2002, 22(23): 8204-8214.
Lewin T M, Wang P, Coleman R A. Analysis of amino acid motifs diagnostic for the sn-glycerol-3-phosphate acyltransferase reaction[J]. Biochemistry, 1999, 38(18): 5764-5771.
Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome[J]. Hepatology, 2003, 37(4): 917-923.
系統作製戦略
The sequences from the start codon to downstream of the 3'UTR of the mouse Gpam gene were replaced with the sequences from the start codon to downstream of the 3'UTR of the human GPAM gene.
Figure 1. Gene editing strategy of huGPAM mice.
適用分野
Research on lipid metabolism and energy homeostasis regulation;
Study of pathogenesis and drug evaluation for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH);
Research on obesity, insulin resistance, and type 2 diabetes;
Targeted drug screening and efficacy evaluation for triglyceride synthesis-related metabolic pathways;
Functional study of mitochondrial glycerol-3-phosphate acyltransferase.
お問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。